Clinical Trial Update: Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD [Phase 3]

View source ↗

Summary

A Phase 3 randomized study evaluated ranibizumab 0.5 mg using treat-extend and monthly regimens in neovascular age-related macular degeneration, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Age-related Macular Degeneration, Choroidal Neovascularization | Phase 3 | Status: COMPLETED | Results posted: 2016-12-15